Published in Cancer Metastasis Rev on March 01, 2007
Probing the ATP Site of GRP78 with Nucleotide Triphosphate Analogs. PLoS One (2016) 1.38
Crystal structure of a concentrative nucleoside transporter from Vibrio cholerae at 2.4 Å. Nature (2012) 1.09
Reduced ribavirin antiviral efficacy via nucleoside transporter-mediated drug resistance. J Virol (2009) 1.07
Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem Rev (2009) 1.06
Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia (2010) 1.04
Nucleobase transport by human equilibrative nucleoside transporter 1 (hENT1). J Biol Chem (2011) 1.04
Tissue distribution, ontogeny and induction of the transporters Multidrug and toxin extrusion (MATE) 1 and MATE2 mRNA expression levels in mice. Life Sci (2008) 1.02
Modular polymer-caged nanobins as a theranostic platform with enhanced magnetic resonance relaxivity and pH-responsive drug release. Angew Chem Int Ed Engl (2010) 0.98
Red fluorescent protein pH biosensor to detect concentrative nucleoside transport. J Biol Chem (2009) 0.97
Cell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirin. PLoS One (2010) 0.95
Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates. J Control Release (2013) 0.91
Identification of the intracellular gate for a member of the equilibrative nucleoside transporter (ENT) family. J Biol Chem (2014) 0.91
Bench-to-bedside review: adenosine receptors--promising targets in acute lung injury? Crit Care (2008) 0.85
In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase. Cancer Chemother Pharmacol (2012) 0.85
Gemcitabine intercellular diffusion mediated by gap junctions: new implications for cancer therapy. Mol Cancer (2010) 0.83
[Not Available]. J Oncol (2009) 0.81
Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients. J Transl Med (2014) 0.81
DNA repair mechanisms in cancer development and therapy. Front Genet (2015) 0.78
Host-based ribavirin resistance influences hepatitis C virus replication and treatment response. J Virol (2011) 0.78
PharmGKB summary: gemcitabine pathway. Pharmacogenet Genomics (2014) 0.78
Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors. Ann Oncol (2015) 0.78
Visualizing multistep elevator-like transitions of a nucleoside transporter. Nature (2017) 0.76
4,5,6-Tri-O-acetyl-2,3-di-S-ethyl-2,3-dithio-d-allose diethyl dithio-acetal. Acta Crystallogr Sect E Struct Rep Online (2009) 0.75
Selective Inhibition of Human Equilibrative and Concentrative Nucleoside Transporters by BCR-ABL Kinase Inhibitors: IDENTIFICATION OF KEY hENT1 AMINO ACID RESIDUES FOR INTERACTION WITH BCR-ABL KINASE INHIBITORS. J Biol Chem (2016) 0.75
Identification of 8-aminoadenosine derivatives as a new class of human concentrative nucleoside transporter 2 inhibitors. ACS Med Chem Lett (2015) 0.75
Base-modified thymidines capable of terminating DNA synthesis are novel bioactive compounds with activity in cancer cells. Bioorg Med Chem (2015) 0.75
N-linked glycosylation of N48 is required for equilibrative nucleoside transporter 1 (ENT1) function. Biosci Rep (2016) 0.75
A metal-containing nucleoside that possesses both therapeutic and diagnostic activity against cancer. J Biol Chem (2015) 0.75
Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine. Front Pharmacol (2017) 0.75
A novel in vitro assay to assess phosphorylation of 3'-[(18)F]fluoro-3'-deoxythymidine. Mol Imaging Biol (2011) 0.75
In Vitro and In Vivo Comparison of Gemcitabine and the Gemcitabine Analog 1-(2'-deoxy-2'-fluoroarabinofuranosyl) Cytosine (FAC) in Human Orthotopic and Genetically Modified Mouse Pancreatic Cancer Models. Mol Imaging Biol (2017) 0.75
Predictive role of human equilibrative nucleoside transporter 1 in patients with pancreatic cancer treated by curative resection and gemcitabine-only adjuvant chemotherapy. Oncol Lett (2017) 0.75
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol (2008) 6.31
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology (2008) 3.28
The equilibrative nucleoside transporter family, SLC29. Pflugers Arch (2003) 3.00
Insulin storage and glucose homeostasis in mice null for the granule zinc transporter ZnT8 and studies of the type 2 diabetes-associated variants. Diabetes (2009) 2.92
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol (2012) 2.65
Rab11-FIP3 and FIP4 interact with Arf6 and the exocyst to control membrane traffic in cytokinesis. EMBO J (2005) 2.64
The molecular architecture of the mammalian DNA repair enzyme, polynucleotide kinase. Mol Cell (2005) 2.09
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res (2004) 2.06
Crystal structure of a prokaryotic homologue of the mammalian oligopeptide-proton symporters, PepT1 and PepT2. EMBO J (2010) 2.05
Quantitative proteomics reveals posttranslational control as a regulatory factor in primary hematopoietic stem cells. Blood (2006) 1.92
Characterization of the role of the AMP-activated protein kinase in the stimulation of glucose transport in skeletal muscle cells. Biochem J (2002) 1.87
Activation of GLUT1 by metabolic and osmotic stress: potential involvement of AMP-activated protein kinase (AMPK). J Cell Sci (2002) 1.79
Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem (2005) 1.75
Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene (2003) 1.73
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology (2012) 1.67
Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH. Circ Res (2006) 1.63
Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res (2009) 1.62
Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol Sci (2006) 1.60
Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clin Cancer Res (2002) 1.55
Effects of controlled discontinuation of long-term used antipsychotics on weight and metabolic parameters in individuals with intellectual disability. J Clin Psychopharmacol (2013) 1.38
The transition state for folding of an outer membrane protein. Proc Natl Acad Sci U S A (2010) 1.37
Interleukin-3-mediated cell survival signals include phosphatidylinositol 3-kinase-dependent translocation of the glucose transporter GLUT1 to the cell surface. J Biol Chem (2003) 1.31
Activation of the Cl- channel ANO1 by localized calcium signals in nociceptive sensory neurons requires coupling with the IP3 receptor. Sci Signal (2013) 1.29
Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Oncogene (2005) 1.25
Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res (2006) 1.24
Mutation of residue 33 of human equilibrative nucleoside transporters 1 and 2 alters sensitivity to inhibition of transport by dilazep and dipyridamole. J Biol Chem (2001) 1.18
The role of human nucleoside transporters in uptake of 3'-deoxy-3'-fluorothymidine. Mol Pharmacol (2008) 1.14
Molecular biology of nucleoside transporters and their distributions and functions in the brain. Curr Top Med Chem (2011) 1.14
The N-terminal helix is a post-assembly clamp in the bacterial outer membrane protein PagP. J Mol Biol (2007) 1.13
Constitutive protein secretion from the trans-Golgi network to the plasma membrane. Mol Membr Biol (2003) 1.12
Functional and structural characterization of the first prokaryotic member of the L-amino acid transporter (LAT) family: a model for APC transporters. J Biol Chem (2007) 1.11
A rare mutation in ABCC8/SUR1 leading to altered ATP-sensitive K+ channel activity and beta-cell glucose sensing is associated with type 2 diabetes in adults. Diabetes (2008) 1.10
Single nucleotide polymorphisms that were identified in affective mood disorders affect ATP-activated P2X7 receptor functions. J Psychiatr Res (2009) 1.10
The oligomeric state and arrangement of the active bacterial translocon. J Biol Chem (2010) 1.09
Transmembrane water-flux through SLC4A11: a route defective in genetic corneal diseases. Hum Mol Genet (2013) 1.09
Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer (2010) 1.09
Potential novel candidate polymorphisms identified in genome-wide association study for breast cancer susceptibility. Hum Genet (2011) 1.08
Mammalian exocyst complex is required for the docking step of insulin vesicle exocytosis. J Biol Chem (2005) 1.07
XRCC1 stimulates polynucleotide kinase by enhancing its damage discrimination and displacement from DNA repair intermediates. J Biol Chem (2007) 1.06
The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. Mol Aspects Med (2013) 1.06
A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol Pharmacol (2005) 1.06
Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. Cancer Res (2008) 1.05
Nucleobase transport by human equilibrative nucleoside transporter 1 (hENT1). J Biol Chem (2011) 1.04
Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. Leuk Res (2007) 1.03
Biophysical characterization of human XRCC1 and its binding to damaged and undamaged DNA. Biochemistry (2004) 1.03
3D reconstruction of mammalian septin filaments. J Mol Biol (2007) 1.02
The nucleoside transport proteins, NupC and NupG, from Escherichia coli: specific structural motifs necessary for the binding of ligands. Org Biomol Chem (2005) 1.01
Intrinsic acyl-CoA thioesterase activity of a peroxisomal ATP binding cassette transporter is required for transport and metabolism of fatty acids. Proc Natl Acad Sci U S A (2013) 1.01
Biodistribution and uptake of 3'-deoxy-3'-fluorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model. J Nucl Med (2010) 1.00
Human SLC2A9a and SLC2A9b isoforms mediate electrogenic transport of urate with different characteristics in the presence of hexoses. Am J Physiol Renal Physiol (2012) 1.00
Cloning and functional characterization of the human GLUT7 isoform SLC2A7 from the small intestine. Am J Physiol Gastrointest Liver Physiol (2004) 0.99
The role of membrane transporters in cellular resistance to anticancer nucleoside drugs. Cancer Treat Res (2002) 0.99
Insights into the Molecular Mechanisms Underlying Mammalian P2X7 Receptor Functions and Contributions in Diseases, Revealed by Structural Modeling and Single Nucleotide Polymorphisms. Front Pharmacol (2013) 0.97
Red fluorescent protein pH biosensor to detect concentrative nucleoside transport. J Biol Chem (2009) 0.97
Modeling, docking, and simulation of the major facilitator superfamily. Biophys J (2006) 0.97
Mutations in the Arabidopsis peroxisomal ABC transporter COMATOSE allow differentiation between multiple functions in planta: insights from an allelic series. Mol Biol Cell (2008) 0.96
Assessing SNP-SNP interactions among DNA repair, modification and metabolism related pathway genes in breast cancer susceptibility. PLoS One (2013) 0.96
The Arabidopsis peroxisomal ABC transporter, comatose, complements the Saccharomyces cerevisiae pxa1 pxa2Delta mutant for metabolism of long-chain fatty acids and exhibits fatty acyl-CoA-stimulated ATPase activity. J Biol Chem (2010) 0.96
Nucleoside transport as a potential target for chemotherapy in malaria. Curr Pharm Des (2007) 0.96
Cloning, heterologous expression, and in situ characterization of the first high affinity nucleobase transporter from a protozoan. J Biol Chem (2003) 0.96
Stomatin-deficient cryohydrocytosis results from mutations in SLC2A1: a novel form of GLUT1 deficiency syndrome. Blood (2011) 0.95
Localization of broadly selective equilibrative and concentrative nucleoside transporters, hENT1 and hCNT3, in human kidney. Am J Physiol Renal Physiol (2007) 0.95
Residues 155 and 348 contribute to the determination of P2X7 receptor function via distinct mechanisms revealed by single-nucleotide polymorphisms. J Biol Chem (2011) 0.95
Studies of nucleoside transporters using novel autofluorescent nucleoside probes. Biochemistry (2006) 0.95
Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC). Curr Cancer Drug Targets (2011) 0.94
Equilibrative nucleoside transporters of Arabidopsis thaliana. cDNA cloning, expression pattern, and analysis of transport activities. J Biol Chem (2003) 0.94
Electrophysiological characterization of a recombinant human Na+-coupled nucleoside transporter (hCNT1) produced in Xenopus oocytes. J Physiol (2004) 0.94